About Simulations Plus
Simulations Plus is a company based in Lancaster (United States) founded in 1996. The company has 197 employees as of August 31, 2023. Simulations Plus has completed 5 acquisitions, including Cognigen, DILIsym and DILIsym Services. Simulations Plus offers products and services including GastroPlus, ADMET Predictor, MonolixSuite, and DILIsym. Simulations Plus operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Lancaster, United States
- Employees 197 as on 31 Aug, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Simulations Plus, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Simulations Plus
Simulations Plus is a publicly listed company on the NASDAQ with ticker symbol SLP in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Simulations Plus
Simulations Plus offers a comprehensive portfolio of products and services, including GastroPlus, ADMET Predictor, MonolixSuite, and DILIsym.
Simulates drug absorption and pharmacokinetics for development research.
Predicts metabolic properties using machine learning for drug safety.
Facilitates pharmacometrics modeling and simulation for clinical trials.
Models liver injury risks in drug development processes.
People of Simulations Plus
Unlock access to complete
Unlock access to complete
Funding Insights of Simulations Plus
Investors in Simulations Plus
Simulations Plus has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and U.S. Food and Drug Administration.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Simulations Plus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Simulations Plus
Simulations Plus has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Cognigen, DILIsym and DILIsym Services.
Investment portfolio details for Simulations Plus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Quantitative toxicology software is provided for drug development processes.
|
Locked | Locked | 2014 | Locked | |
|
Pharmaceutical, consulting, and concierge services are provided.
|
Locked | Locked | 2014 | Locked | |
|
Modeling and simulation software for drug development is developed.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Simulations Plus
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Simulations Plus
Detailed financials for Simulations Plus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Simulations Plus Comparisons
Peer comparison for Simulations Plus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Simulations Plus
Simulations Plus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Simulations Plus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Simulations Plus
Complete news archive for Simulations Plus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Simulations Plus
Simulations Plus was founded in 1996 and raised its 1st funding round 11 years after it was founded.
Simulations Plus is headquartered in Lancaster, United States. It is registered at Lancaster, Pennsylvania, United States.
As of Aug 31, 2023, the latest employee count at Simulations Plus is 197.
Annual revenue of Simulations Plus is $79.18M as on Aug 31, 2025.
Founded in 1996 and based in Lancaster, United States, Simulations Plus operates in the chemoinformatics and drug discovery sector. Eight software packages are offered, including GastroPlus for PKPD simulations in humans and animals, DDDPlus for formulation dissolution modeling, and ADMET Predictor for ADME property predictions. Additional tools support molecule sketching, data mining, and cloud storage. Services encompass regulatory strategies, pharmacometrics, and modeling solutions.
Simulations Plus's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Simulations Plus offers GastroPlus, ADMET Predictor, MonolixSuite, and DILIsym.
Yes, Simulations Plus is publicly traded on NASDAQ under the ticker symbol SLP.
Simulations Plus has made 5 acquisitions, including Cognigen, DILIsym, and DILIsym Services.
Simulations Plus has 3 investors. Key investors include NIH, HHS, and U.S. Food and Drug Administration.
The ticker symbol of Simulations Plus is SLP on NASDAQ.